Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).

ESMO open·2026
Same author

Cytokine release symptoms rather than syndromes: a call for granular reporting of cytokine-related adverse events in clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

From algorithms to meaningful biomarkers: anchoring AI in clinical oncology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

ESMO open·2025
Same author

ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

ESMO open·2025

Related Experiment Video

Updated: May 3, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.3K

Targeting Regulatory T Cells for Cancer Immunotherapy: Promises and Pitfalls.

O Mirallas1, G Pretelli2, M Balsa3

  • 1Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Research Unit for Molecular Therapy of Cancer (UITM), Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Department of Medicine, Universidad Autónoma de Barcelona, Barcelona, Spain.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 1, 2026
PubMed
Summary

Regulatory T cells (Tregs) are crucial for immune balance but can aid tumor growth. Therapies targeting Tregs show promise but require careful balance to avoid immune suppression and maximize anti-tumor effects.

Keywords:
FOXP3immune suppressionimmune toleranceimmunotherapyregulatory T cells (Tregs)tumor microenvironment

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.8K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Related Experiment Videos

Last Updated: May 3, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

5.3K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.8K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Regulatory T cells (Tregs) are essential for immune homeostasis and preventing autoimmunity.
  • Tregs express CD25 and CTLA-4, and in mice, are defined by FOXP3.
  • While vital for tolerance, Tregs can be exploited by tumors to promote immune escape and progression.

Purpose of the Study:

  • To review Treg biology and their role in cancer immunity.
  • To summarize emerging therapeutic strategies for modulating Tregs in cancer.
  • To discuss limitations and future directions in Treg-targeted cancer therapies.

Main Methods:

  • Targeted literature review of major databases (PubMed, Web of Science, ClinicalTrials.gov).
  • Inclusion of conference abstracts from ASCO/ESMO.
  • Manual screening of references for comprehensive coverage.

Main Results:

  • Therapeutic strategies include Treg depletion (anti-CD25, anti-CCR4), functional blockade (CTLA-4, TIGIT), and metabolic pathway disruption.
  • Preclinical studies show antitumor effects, but clinical trials report variable efficacy and toxicity.
  • Newer strategies focus on selectively targeting intratumoral Tregs, potentially guided by FOXP3+Helios+CCR8+ subsets.

Conclusions:

  • Further understanding of Treg regulation is necessary for effective cancer therapy.
  • Balancing Treg modulation is critical to harness therapeutic potential without compromising immune equilibrium.